Large-scale production and purification of VLP-based vaccines.
about
Ebolavirus vaccines for humans and apesChikungunya vaccines in developmentManufacturing of AcMNPV baculovirus vectors to enable gene therapy trialsCurrent and emerging cell culture manufacturing technologies for influenza vaccines.Critical assessment of influenza VLP production in Sf9 and HEK293 expression systems.Immune responses in mice vaccinated with virus-like particles composed of the GP5 and M proteins of porcine reproductive and respiratory syndrome virus.The choice of resin-bound ligand affects the structure and immunogenicity of column-purified human papillomavirus type 16 virus-like particlesAdditive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteinsEffective chikungunya virus-like particle vaccine produced in insect cells.Improved Production Efficiency of Virus-Like Particles by the Baculovirus Expression Vector SystemStability studies of HIV-1 Pr55gag virus-like particles made in insect cells after storage in various formulation media.Plant-derived virus-like particles as vaccinesSelf-assembly of hexahistidine-tagged tobacco etch virus capsid protein into microfilaments that induce IgG2-specific response against a soluble porcine reproductive and respiratory syndrome virus chimeric proteinConstruction and characterization of virus-like particles: a review.Protein production using the baculovirus-insect cell expression system.Suitability and perspectives on using recombinant insect cells for the production of virus-like particles.Enveloped virus-like particles as vaccines against pathogenic arboviruses.Next generation vaccines and vectors: Designing downstream processes for recombinant protein-based virus-like particles.Biomolecular engineering of virus-like particles aided by computational chemistry methods.Different applications of virus-like particles in biology and medicine: Vaccination and delivery systems.Development of a porcine reproductive and respiratory syndrome virus-like-particle-based vaccine and evaluation of its immunogenicity in pigs.Enterovirus71 virus-like particles produced from insect cells and purified by multistep chromatography elicit strong humoral immune responses in mice.Use of uniform designs in combination with neural networks for viral infection process development.Efficient production of Japanese encephalitis virus-like particles by recombinant lepidopteran insect cells.Kinetics of infected insect cell osmolysis and enhanced protein release using a modified disruption method.Production of Japanese Encephalitis Virus-Like Particles Using Insect Cell Expression Systems.Production of Japanese encephalitis virus-like particles in insect cells.Improving the baculovirus expression vector system with vankyrin-enhanced technology.Virus-like particle-based countermeasures against Rift Valley fever virus.Adenovirus Dodecahedron, a VLP, Can be Purified by Size Exclusion Chromatography Instead of Time-Consuming Sucrose Density Gradient Centrifugation.Secretion and assembly of calicivirus-like particles in high-cell-density yeast fermentations: strategies based on a recombinant non-specific BPTI-Kunitz-type protease inhibitor.Characterization and immunogenicity of norovirus capsid-derived virus-like particles purified by anion exchange chromatography.The production and immunogenicity of human papillomavirus type 58 virus-like particles produced in Saccharomyces cerevisiae.A new single-step protocol for rapid baculovirus-driven protein production in insect cells.Preclinical Development and Production of Virus-Like Particles As Vaccine Candidates for Hepatitis C.Industrial Large Scale of Suspension Culture of Insect Cells
P2860
Q24631696-99B599F5-78BE-45A7-BA2E-8A409135C989Q26700081-BD755AB6-A83D-4E04-BBDB-CEB37739062BQ26767368-2F66D773-2D8B-430D-81E0-6C92902D5440Q30373128-B2CCBC85-F5C3-401B-9970-0962796256A0Q30374733-8FC34798-65E6-4959-A4A2-7713B4370912Q34019891-915C0CF8-95A9-44F3-88B5-99768D192F7FQ34259805-46E53340-311A-4D7B-A6AE-44B4A427ECB7Q34616642-D5F68460-30F4-4BA1-985E-3F945CA631EAQ34630576-64C4AC36-6D85-441B-9ADD-EBA4FCFBE2BFQ35803488-FBEB388A-2BB0-4BCE-8E8D-56E10E827959Q36412202-B52F1C02-E4C5-40AE-AB17-9D4A393A3AE1Q36888029-691D7AEA-B8BA-449F-8FD9-665878074B20Q37449926-C973EF90-8880-49D9-86FC-A2117BAF4452Q38045834-22734E27-9BE8-4659-939C-39B762ECAFBDQ38165127-2DE2F82E-7C43-41B9-BA22-774A009B4039Q38177170-1C336CFA-9D84-4471-9A49-C8CFA17F37A7Q38359973-E7A4CA20-796F-4C4B-B831-A1C317EF2D85Q38423724-9644A487-5F62-4350-9CBB-5960415C2F7AQ38588882-5995E92F-1857-4198-ABE3-6F9C61072C40Q38618258-FDE973F8-B71E-4E3E-AF3D-214DB19AE8E4Q38783810-2655D8AC-996C-4569-8F4F-116A09AA4DD8Q38845816-774E8FFC-28BF-42BD-9D56-983DF677A966Q38915820-087AFB74-1DCB-4841-9FD1-39863AE201F4Q39285419-883CBAAF-8A84-469B-85FC-16179E4A15AEQ39584243-2B0D648B-59A6-4500-BACD-F71D45DC115CQ39611070-D5B3F7D9-4358-4840-B978-BD130C208799Q39611076-2DA4612A-FDE6-401C-9A65-12154D97E809Q40158347-91A9F92D-499C-499B-AA2A-352507F26C50Q40254473-07A01C64-B941-4A9A-9C40-BFF9DEE78A83Q42160175-464290AA-2F26-4A45-BCC2-3785F06F4932Q42181296-89910759-5190-4C18-B311-858A20D78963Q44197060-BD6EAA29-B0E1-424C-94F8-E42AD2449977Q45354037-CB97A482-7238-4531-9B0C-BE2098BFBE9CQ46674831-62932406-5D68-4645-A042-CC130F35FC98Q47100523-EC802F55-79A5-419E-9F3D-88345A3E3B02Q58753697-AA146E6A-B54F-4FF4-BA1F-6D6ED1B0EC2B
P2860
Large-scale production and purification of VLP-based vaccines.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Large-scale production and purification of VLP-based vaccines.
@en
Large-scale production and purification of VLP-based vaccines.
@nl
type
label
Large-scale production and purification of VLP-based vaccines.
@en
Large-scale production and purification of VLP-based vaccines.
@nl
prefLabel
Large-scale production and purification of VLP-based vaccines.
@en
Large-scale production and purification of VLP-based vaccines.
@nl
P50
P1476
Large-scale production and purification of VLP-based vaccines.
@en
P2093
António Roldão
Tiago Vicente
P356
10.1016/J.JIP.2011.05.004
P478
P577
2011-07-01T00:00:00Z